Benjamin Garmezy, MD, explains what varying Nectin-4 expression means for treatment selection in bladder cancer and what trials are still needed.
Benjamin Garmezy, MD
Advertisement
Articles by Benjamin Garmezy, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week
2
Clesrovimab Demonstrates Safety Through a Second RSV Season in High-Risk Infants
3
Dry Eye Disease Is More Than "Dry Eyes": Experts Explain the 2 Types
4
Multidisciplinary Teams Improve Biomarker Testing and Lung Cancer Care: Urs Weber, MD
5